Hematologic Diseases  >>  Pegasys (pegylated interferon α -2a)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Roche
AFR07, NCT00763763: Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive

Completed
2
55
Europe
Imatinib mesylate, Interferon, Pegasys, Interferon, Pegasys, Vincristine, Dexamethasone
Assistance Publique - Hôpitaux de Paris
Leukemia, Lymphocytic, Acute, Philadelphia Chromosome, Blast Crisis, Leukemia, Myeloid, Chronic
10/07
01/10
NCT01392170: Pegasys in Patients With Chronic Myeloid Leukemia (CML)

Terminated
2
2
US
PEG-IFNá-2a, Pegasys, Peginterferon Alpha-2a
M.D. Anderson Cancer Center
Leukemia
03/14
03/14
NCT01153919: Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Terminated
2
27
US
romiplostim, AMG 531, Amgen megakaryopoiesis protein 2, Nplate, ribavirin, ICN-1229, Rebetol, RIBA, RTCA, Viramide, Virazole, placebo, PLCB, PEG-interferon alfa-2a, PEG-IFNA2a, PEGASYS, pegylated interferon alfa-2a, laboratory biomarker analysis
University of Southern California
Hepatitis C Infection, Thrombocytopenia
07/14
07/18
MPD-RC 111, NCT01259817 / 2010-019500-23: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

Completed
2
135
US, Europe
PEGASYS, Pegylated Interferon Alfa-2a, Aspirin, acetylsalicylic acid
Ronald Hoffman, Myeloproliferative Disorders-Research Consortium, National Cancer Institute (NCI), Roche Pharma AG
High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
12/16
12/16

Download Options